400 related articles for article (PubMed ID: 37269217)
1. Impact of Nanomedicine in Women's Metastatic Breast Cancer.
Ashkarran AA; Lin Z; Rana J; Bumpers H; Sempere L; Mahmoudi M
Small; 2023 Jun; ():e2301385. PubMed ID: 37269217
[TBL] [Abstract][Full Text] [Related]
2. Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages.
Yu W; Hu C; Gao H
Adv Drug Deliv Rev; 2021 Nov; 178():113909. PubMed ID: 34352354
[TBL] [Abstract][Full Text] [Related]
3. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
4. A rationally designed photo-chemo core-shell nanomedicine for inhibiting the migration of metastatic breast cancer cells followed by photodynamic killing.
Malarvizhi GL; Chandran P; Retnakumari AP; Ramachandran R; Gupta N; Nair S; Koyakutty M
Nanomedicine; 2014 Apr; 10(3):579-87. PubMed ID: 24200524
[TBL] [Abstract][Full Text] [Related]
5. Special Issue: Nanotherapeutics in Women's Health Emerging Nanotechnologies for Triple-Negative Breast Cancer Treatment.
Torres Quintas S; Canha-Borges A; Oliveira MJ; Sarmento B; Castro F
Small; 2023 Mar; ():e2300666. PubMed ID: 36978237
[TBL] [Abstract][Full Text] [Related]
6. Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey.
Liu W; Vivian CJ; Brinker AE; Hampton KR; Lianidou E; Welch DR
Cancer Microenviron; 2014 Dec; 7(3):117-31. PubMed ID: 24938990
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicine-Based Delivery Strategies for Breast Cancer Treatment and Management.
Tagde P; Najda A; Nagpal K; Kulkarni GT; Shah M; Ullah O; Balant S; Rahman MH
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269998
[TBL] [Abstract][Full Text] [Related]
8. Current understandings and clinical translation of nanomedicines for breast cancer therapy.
Jiang Y; Jiang Z; Wang M; Ma L
Adv Drug Deliv Rev; 2022 Jan; 180():114034. PubMed ID: 34736986
[TBL] [Abstract][Full Text] [Related]
9. Nanofibrous drug delivery systems for breast cancer: a review.
Hussain T; Ramakrishna S; Abid S
Nanotechnology; 2021 Dec; 33(10):. PubMed ID: 34757956
[TBL] [Abstract][Full Text] [Related]
10. Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women's Health.
Abderrahman B; Jordan VC
Endocrinology; 2018 Aug; 159(8):2980-2990. PubMed ID: 29931061
[TBL] [Abstract][Full Text] [Related]
11. Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(1):1-32. PubMed ID: 23074501
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients.
Hafizi M; Kalanaky S; Moaiery H; Khayamzadeh M; Noorian S; Kaveh V; Gharib B; Foudazi H; Razavi M; Jenabian A; Salimi S; Sereshki MMA; Mirzaei HR; Zarghi A; Fakharzadeh S; Nazaran MH; Akbari ME
J Nanobiotechnology; 2019 Apr; 17(1):52. PubMed ID: 30971278
[TBL] [Abstract][Full Text] [Related]
13. Emergence in protein derived nanomedicine as anticancer therapeutics: More than a tour de force.
Wang Z; Zhi K; Ding Z; Sun Y; Li S; Li M; Pu K; Zou J
Semin Cancer Biol; 2021 Feb; 69():77-90. PubMed ID: 31962173
[TBL] [Abstract][Full Text] [Related]
14. Radiation therapy for primary tumor of
Yoshimura M
Transl Cancer Res; 2020 Aug; 9(8):5108-5116. PubMed ID: 35117877
[TBL] [Abstract][Full Text] [Related]
15. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
16. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.
Gote V; Nookala AR; Bolla PK; Pal D
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925129
[TBL] [Abstract][Full Text] [Related]
17. Mammography screening: A major issue in medicine.
Autier P; Boniol M
Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in nanotheranostics for triple negative breast cancer treatment.
Thakur V; Kutty RV
J Exp Clin Cancer Res; 2019 Oct; 38(1):430. PubMed ID: 31661003
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel: a new active agent in the therapy of metastatic breast cancer.
Fumoleau P; Seidman AD; Trudeau ME; Chevallier B; Ten Bokkel Huinink WW
Expert Opin Investig Drugs; 1997 Dec; 6(12):1853-65. PubMed ID: 15989586
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
